Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

被引：1

作者：

Bishnoi, S. ^{[1
]}

Cosman, R. ^{[2
]}

Moore, M. ^{[3
]}

Eek, R. ^{[4
]}

Mant, A. ^{[5
]}

Zielinski, R. ^{[6
]}

Chan, L. S. ^{[7
]}

Ma, Y. ^{[8
]}

Zhang, Q. ^{[9
]}

Yau, T. ^{[10
]}

Aghmesheh, M. ^{[11
]}

Tse, A. N. ^{[9
]}

机构：

[1] Ashford Canc Ctr Res, Dept Med Oncol, Adelaide, SA, Australia

[2] St Vincents Hosp, Dept Med Oncol, Sydney, NSW, Australia

[3] Alfred Hosp, Dept Med Oncol, Melbourne, Vic, Australia

[4] Border Med Oncol, Dept Med Oncol, Albury, NSW, Australia

[5] Box Hill Hosp, Dept Oncol, Melbourne, Vic, Australia

[6] Orange Hlth Serv, Oncol Unit, Orange, NSW, Australia

[7] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China

[8] CStone Pharmaceut Su Zhou Co Ltd, Clin Dept, Suzhou, Peoples R China

[9] CStone Pharmaceut Suzhou Co Ltd, Translat Med & Early Dev, Suzhou, Peoples R China

[10] Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China

[11] Southern Mediacal Day Care Ctr, Dept Med Oncol, Wollongong, NSW, Australia

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1365

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

981P

引用

页码：S840 / S840

页数：1

共 50 条

[11] Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
Zhou, Cai
He, Yayi
Ren, Shengxiang
Li, Wei
Zhu, Jun
Yu, Jia
Wang, Lei
Xiong, Anwen
Xu, Nong
Mao, Chenyu
Pan, Beiqing
Liu, Ying
Zhou, Hui
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[12] A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors
Naing, A.
Goel, S.
Curti, B.
Weise, A.
Eder, J. P.
Marshall, S.
Morehouse, C.
Li, X.
Karakunnel, J. J.
Infante, J.
ANNALS OF ONCOLOGY, 2016, 27
[13] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
Xiong, Jianping
Ouyang, Weiwei
Yang, Mengxiang
Gao, Zhenyuan
Zhou, Huan
Lou, Hanmei
Guo, Yabing
Xu, Zhongyuan
Zheng, Ling
Liu, Ying
Wang, Zhongfeng
Sun, Ping
Niyazi, Huerxidan
Wang, Jianhua
Chen, Yan
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
Guo, Weijian
ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
[14] Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.
Oh, Do-Youn
Park, John J.
Lee, Keun Wook
Kim, Seung Tae
Sriuranpong, Virote
Rha, Sun Young
Yoo, Changhoon
Keam, Bhumsuk
Sabanathan, Dhanusha
Kim, Se Hyun
Park, Joon Oh
Parinyanitikul, Napa
Kim, Min Hwan
Kim, Kyu-Pyo
Kim, Myungsuk
Yoon, Jaebong
Lee, Han Seung
Ock, Chan-Young
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[15] Interim results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) monotherapy and in combination with toripalimab (an anti-PD-1 antibody) in patients (pts) with advanced/metastatic solid tumors
Ariyapperuma, Mihitha
Park, John J.
Khattak, Adnan
Richardson, Gary
Hamid, Anis
Morris, Michelle
Tolcher, Anthony W.
Goh, Boon Cher
Lam, Justina
Chmielowski, Bartosz
She, Kristine
Zhang, Yanyan
Li, Ai
Zheng, Songmao
Liu, Guizhong
Zhu, Lvyu
Wang, Hongyan
Cui, Xiaoxing
Luo, Peter
Zha, Jiping
CANCER RESEARCH, 2023, 83 (08)
[16] A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
Coward, Jermaine
Ben Markman
Nagrial, Adnan
Abed, Afaf
Walpole, Imogen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[17] A first-in-human, phase I, dose-escalation study to evaluate pharmacokinetics, safety, and tolerability of KD6001, a novel anti-CTLA-4 monoclonal antibody (mAb) in patients with advanced solid tumors
Tang, Bixia
Duan, Rong
Li, Siming
Sheng, Xinan
Si, Lu
Cui, Chuanliang
Mao, Lili
Wang, Xuan
Lian, Bin
Wei, Xiaoting
Yan, Xieqiao
Li, Juan
Zhou, Li
Xu, Huayan
Li, Caili
Cai, Zeling
Zhang, Chi
Wang, Fangfang
Guo, Jun
Chi, Zhihong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[18] A PHASE 1B/2 STUDY OF A NOVEL ANTI-CTLA-4 NEOBODYTM ADG116 MONOTHERAPY AND IN COMBINATION WITH TORIPALIMAB (TORI; ANTI-PD-1 ANTIBODY) IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS
Park, John
Hsien, Matthew
Richardson, Gary
Tolcher, Anthony
Chon, Hong Jae
Shin, Sang Joon
Lim, Ho Yeong
Hamid, Anis
Li, Daneng
Shi, Kristine
Zheng, Songmao
Liu, Guizhong
Li, Ai
Zhu, Lvyu
Dai, Ruby
Peng, Wei
Lowe, Dana
Luo, Peter
Zha, Jiping
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A785 - A785
[19] GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial
Shen, Lin
Gong, Jifang
Song, Yuqin
Ye, Dingwei
Lu, Zhihao
Wang, Siyang
Peng, Peijian
Chen, Jianhua
Jiang, Ou
Zhang, Guojun
Bai, Yuxian
Pan, Jianji
Ma, Chunguang
Chen, Li
Ba, Yi
Li, Qi
Lu, Ping
Zhang, Lingli
Yin, Xianli
Gu, Shanzhi
Zhang, Huilai
Su, Hang
Jiang, Yongsheng
Cao, Bangwei
Han, Weiqing
Sun, Yan
Zhang, Feng
Ouyang, Weiwei
Dong, Haiying
Guo, Jianming
Guo, Yabing
Xu, Chongyuan
Qi, Junyuan
Wang, Li
Lv, Jun
Wang, Xiang
Chen, Chris
Li, Jing
Zheng, Yong
Jin, Ge
Yang, Yining
Zhao, Guodong
Yang, Fan
Xu, Kehui
Liang, Xiangying
Pan, Zhaoyang
Meng, Haijin
CANCER RESEARCH, 2020, 80 (16)
[20] Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors
De Miguel, M.
Landa Magdalena, A.
Moreno Garcia, V.
Gambardella, V.
Menis, J.
Daniele, G.
El-Khoueiry, A. B.
Spira, A. I.
Gravina, A.
Olszanski, A. J.
Rapaic, O.
Li, J.
Poullain, H.
Margall, G.
Wong, G.
Hedrich, W.
Pollard, J. Russella
Gan, J.
Shi, X.
Andtbacka, R. H. I.
ANNALS OF ONCOLOGY, 2024, 35 : S684 - S684

← 1 2 3 4 5 →